BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Perrotta G, Metens T, Absil J, Lemort M, Manto M. Absence of clinical cerebellar syndrome after serial injections of more than 20 doses of gadoterate, a macrocyclic GBCA: a monocenter retrospective study. J Neurol 2017;264:2277-83. [PMID: 28956156 DOI: 10.1007/s00415-017-8631-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Mallio CA, Rovira À, Parizel PM, Quattrocchi CC. Exposure to gadolinium and neurotoxicity: current status of preclinical and clinical studies. Neuroradiology 2020;62:925-34. [DOI: 10.1007/s00234-020-02434-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
2 Lancelot E, Raynaud J, Desché P. Current and Future MR Contrast Agents: Seeking a Better Chemical Stability and Relaxivity for Optimal Safety and Efficacy. Invest Radiol 2020;55:578-88. [DOI: 10.1097/rli.0000000000000684] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
3 Kühn I, Maschke H, Großmann A, Hauenstein K, Weber MA, Zettl UK, Storch A, Walter U. Dentate-nucleus gadolinium deposition on magnetic resonance imaging: ultrasonographic and clinical correlates in multiple sclerosis patients. Neurol Sci 2021. [PMID: 34735650 DOI: 10.1007/s10072-021-05702-4] [Reference Citation Analysis]
4 Topcuoglu ED, Topcuoglu OM, Semiz Oysu A, Bukte Y. Does Gadoterate Meglumine Cause Gadolinium Retention in the Brain of Children? A Case-Control Study. J Magn Reson Imaging 2020;51:1471-7. [PMID: 31665554 DOI: 10.1002/jmri.26954] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
5 Young LK, Matthew SZ, Houston JG. Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals. Eur Radiol 2019;29:1922-30. [PMID: 30276674 DOI: 10.1007/s00330-018-5737-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
6 Zivadinov R, Bergsland N, Hagemeier J, Ramasamy DP, Dwyer MG, Schweser F, Kolb C, Weinstock-Guttman B, Hojnacki D. Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. Neurology 2019;93:e611-23. [PMID: 31285398 DOI: 10.1212/WNL.0000000000007892] [Cited by in Crossref: 18] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
7 DeBevits JJ 4th, Munbodh R, Bageac D, Wu R, DiCamillo PA, Hu C, Wang L, Naismith RT, Karimeddini D, Dhib-Jalbut S, Redko S, Cook SD, Cadavid D, Wolansky L. Gray Matter Nucleus Hyperintensity After Monthly Triple-Dose Gadopentetate Dimeglumine With Long-term Magnetic Resonance Imaging. Invest Radiol 2020;55:629-35. [PMID: 32898355 DOI: 10.1097/RLI.0000000000000663] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Khairinisa MA, Ariyani W, Tsushima Y, Koibuchi N. Effects of Gadolinium Deposits in the Cerebellum: Reviewing the Literature from In Vitro Laboratory Studies to In Vivo Human Investigations. Int J Environ Res Public Health 2021;18:7214. [PMID: 34299664 DOI: 10.3390/ijerph18147214] [Reference Citation Analysis]
9 Guo BJ, Yang ZL, Zhang LJ. Gadolinium Deposition in Brain: Current Scientific Evidence and Future Perspectives. Front Mol Neurosci 2018;11:335. [PMID: 30294259 DOI: 10.3389/fnmol.2018.00335] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 16.3] [Reference Citation Analysis]
10 Ariyani W, Khairinisa MA, Perrotta G, Manto M, Koibuchi N. The Effects of Gadolinium-Based Contrast Agents on the Cerebellum: from Basic Research to Neurological Practice and from Pregnancy to Adulthood. Cerebellum 2018;17:247-51. [PMID: 29196974 DOI: 10.1007/s12311-017-0903-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]